Medivation
Company

Last deal

Amount

Post-IPO Equity

Stage

01.03.2008

Date

1

all rounds

date founded

Financing round

General

About Company
Medivation, Inc. is a biopharmaceutical company that develops small molecule drugs for serious diseases with limited treatment options.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2003

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's collaboration with Astellas Pharma Inc. focuses on developing MDV3100 for advanced prostate cancer. Medivation has three subsidiaries, each with different technologies in development for advanced prostate cancer, Alzheimer's disease, and Huntington disease. Medivation's goal is to transform treatment options for critically ill patients and their families, and with the approval of Xtandi, the company is continuing to grow its workforce to reach the next strategic level.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Strongbridge Biopharma

Strongbridge Biopharma

Strongbridge Biopharma is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Dublin, Ireland

total rounds

7

total raised

$196.5M
Kadmon

Kadmon

Kadmon Corporation is a biopharmaceutical company specializing in treatments for hepatitis C.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

New York, NY, USA

total rounds

9

total raised

$629.47M
Curtana Pharmaceuticals

Curtana Pharmaceuticals

Curtana is a biopharmaceutical company that develops therapies for aggressive brain cancer.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Austin, TX, USA

total rounds

3

total raised

$52.29K
Dyax

Dyax

Dyax Corp. is a biopharmaceutical company that develops and commercializes biotherapeutics for unmet medical needs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Cambridge, MA, USA
M&A Details
1

Transaction name

Acquired by

Pfizer

announced date

22.08.2016

price

$14B

Financials

Funding Rounds
1
1

Number of Funding Rounds

Their latest funding was raised on 01.03.2008. Their latest investor Plough Penny Partners. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Plough Penny Partners

Plough Penny Partners

Plough Penny Partners is a private investment firm that invests in publicly traded and privately-held companies.

Sector

Real Estate Investment and Services Development

Subsector

Real Estate Holding and Development

Keywords

Financial Services, Venture Capital, Real Estate

Location

New York, NY, USA

count Of Investments

20

count Of Exists

9
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Equity
Plough Penny Partners

Plough Penny Partners

Plough Penny Partners is a private investment firm that invests in publicly traded and privately-held companies.

Sector

Real Estate Investment and Services Development

Subsector

Real Estate Holding and Development

Keywords

Financial Services, Venture Capital, Real Estate

Location

New York, NY, USA

count Of Investments

20

count Of Exists

9

People

Founders
2
David Hung
David Hung

David Hung

Dr. David T. Hung, M.D. has been President, Chief Executive Officer, Director of Medivation, Inc. He is a member of the Board, since December 2004. Previously, Dr. Hung served as the President and Chief Executive Officer, and member of the board of directors, of Medivation Neurology, Inc. from its inception in September 2003 through December 2004, when it became the wholly owned subsidiary by merger. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999) and as President and Chief Executive Officer (1999-2001). Dr. Hung served as a consultant to Cytyc Corporation from 2001 until 2002 to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Dr. Hung is a director and member of the compensation committee of Opexa. Dr. Hung received an M.D. from the University of California, San Francisco, School of Medicine, and an A.B. in Biology from Harvard College. Dr. Hung is a co-founder of Medivation, has served as the President and Chief Executive Officer since inception, and is responsible for the overall corporate strategy and selection of the product development candidates.

current job

Nuvation Bio
Nuvation Bio

organization founded

2

David Hung

Michael J. Cataldo
Michael J. Cataldo

Michael J. Cataldo

Mike is CEO of Convergent Dental, an early stage dental device company backed by Long River Ventures. The company has developed Solea, a device that will eliminate the drill for the majority of dental procedures and along with it, the noise, vibration and needle that cause patients to dread going to the dentist. This disruptive innovation was completed within 18 months of the company’s inception and is now rated best-in-class for both hard and soft tissue cutting by leading laser dentists. Prior to Convergent Dental, Mike was CEO of Cambridge Semantics, a Boston-based start-up which delivered the first development platform for the World Wide Web Consortium’s semantic technology standards. In 1997 he founded MediVation, which developed the first Electronic Provider Patient Interface connecting patients with their own doctors via the Internet. MediVation was acquired by McKesson in 2000.

current job

Convergent Dental
Convergent Dental

Michael J. Cataldo

Employee Profiles
165

Jane Varian

Senior medical science liaison

Warren Shubin

Senior analyst, solutions delivery

Facmt Javier Waksman

Head of drug safety and pharmacovigilance

Tiffany Locke

Senior sales specialist

Cantillon Eilers

Sales representative urology and oncology

Jill Liu

Senior director, technical accounting and external reporting

Abdul Khan

Security engineer

Kathleen Morris

Clinical study assistant

Activity

Recent News
0